Croissance Clinical Research Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 7.00 M
as on 31-07-2024
- Paid Up Capital ₹ 6.82 M
as on 31-07-2024
- Company Age 11 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 16.50 M
as on 31-07-2024
- Revenue -14.07%
(FY 2023)
- Profit -34.07%
(FY 2023)
- Ebitda -27.53%
(FY 2023)
- Net Worth 24.91%
(FY 2023)
- Total Assets 8.15%
(FY 2023)
About Croissance Clinical Research
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.00 M and a paid-up capital of Rs 6.82 M.
The company currently has active open charges totaling ₹1.65 Cr.
Satish Marukurthi and Bharathi Marukurthi serve as directors at the Company.
- CIN/LLPIN
U74900TG2013PTC087677
- Company No.
087677
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 May 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Croissance Clinical Research?
Executive Team (1)
SM
Satish Marukurthi
Managing DirectorAppointment Date: 16-May-2013
Status: Current
Board Members(1)
Financial Performance and Corporate Structure Insights of Croissance Clinical Research.
Croissance Clinical Research Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 14.07% decrease. The company also saw a substantial fall in profitability, with a 34.07% decrease in profit. The company's net worth Soared by an impressive increase of 24.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Croissance Clinical Research?
In 2023, Croissance Clinical Research had a promoter holding of 78.00% and a public holding of 22.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Brridge Clinical Research Services Private Limited
Active
9 years 8 months Satish Marukurthi and Bharathi Marukurthi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Jan 2021 | ₹6.50 M | Open |
Hdfc Bank Limited Creation Date: 10 Jul 2020 | ₹1.00 Cr | Open |
How Many Employees Work at Croissance Clinical Research?
Croissance Clinical Research has a workforce of 11 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Apr 16, 2015, Croissance Clinical Research has raised a total of ₹ 1.23 Cr, with the most recent deal valued at ₹ 6.17 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
